|
Rhabdomyosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rhabdomyosarcomas are malignancies associated with a rhabdomyoblastic phenotype which can be demonstrated morphologically or by immunohistochemistry for MYOD1 and myogenin.
|
31696361 |
2020 |
|
Malignant Neoplasms
|
0.370 |
GeneticVariation
|
group |
BEFREE |
Rhabdomyosarcomas are malignancies associated with a rhabdomyoblastic phenotype which can be demonstrated morphologically or by immunohistochemistry for MYOD1 and myogenin.
|
31696361 |
2020 |
|
Rhabdomyosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated 30 cases of MYOD1-mutant rhabdomyosarcoma (12 previously reported and 18 newly diagnosed) with an age range of 2-94 years, including 15 children.
|
30181563 |
2019 |
|
Rhabdomyosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
|
30604891 |
2019 |
|
Rhabdomyosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cases were wild type for MYOD1 and no other mutations or rearrangements characteristic of a known subtype of rhabdomyoma or rhabdomyosarcoma were identified.
|
30287926 |
2019 |
|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
Using four different groups of biopsies obtained from gastric body without history of H. pylori infection (Hp-), gastric body without cancer after H. pylori eradication (cancer-free body), gastric body with early gastric cancer diagnosed after H. pylori eradication (EGC body) and their paired samples from adjacent mucosa of cancer (EGC ADJ), methylation status of five candidate genes (MYOD1, SLC16A12, IGF2, RORA and PRDM5) was examined by the bisulfite pyrosequencing.
|
29978464 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, we report 2 novel fusions (PAX3-WWTR1 and PAX3-NCOA2) in BSNS and show that MyoD1 is more sensitive than myogenin for demonstrating myogenic differentiation in this tumor.
|
30829729 |
2019 |
|
Childhood Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated 30 cases of MYOD1-mutant rhabdomyosarcoma (12 previously reported and 18 newly diagnosed) with an age range of 2-94 years, including 15 children.
|
30181563 |
2019 |
|
Childhood Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cases were wild type for MYOD1 and no other mutations or rearrangements characteristic of a known subtype of rhabdomyoma or rhabdomyosarcoma were identified.
|
30287926 |
2019 |
|
Adult Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cases were wild type for MYOD1 and no other mutations or rearrangements characteristic of a known subtype of rhabdomyoma or rhabdomyosarcoma were identified.
|
30287926 |
2019 |
|
Adult Rhabdomyosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated 30 cases of MYOD1-mutant rhabdomyosarcoma (12 previously reported and 18 newly diagnosed) with an age range of 2-94 years, including 15 children.
|
30181563 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Using four different groups of biopsies obtained from gastric body without history of H. pylori infection (Hp-), gastric body without cancer after H. pylori eradication (cancer-free body), gastric body with early gastric cancer diagnosed after H. pylori eradication (EGC body) and their paired samples from adjacent mucosa of cancer (EGC ADJ), methylation status of five candidate genes (MYOD1, SLC16A12, IGF2, RORA and PRDM5) was examined by the bisulfite pyrosequencing.
|
29978464 |
2019 |
|
Spindle cell rhabdomyosarcoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Spindle cell rhabdomyosarcoma (RMS) is an aggressive sarcoma type with a predilection for the head and neck and frequent transactivating MYOD1 mutations.
|
31107719 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
At final follow-up (median = 13.5 months), recurrences (n = 4), metastases (n = 2) or both (n = 1) occurred in seven MYOD1-mutant cases; one had died of disease.
|
30604891 |
2019 |
|
Sarcoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Spindle cell rhabdomyosarcoma (RMS) is an aggressive sarcoma type with a predilection for the head and neck and frequent transactivating MYOD1 mutations.
|
31107719 |
2019 |
|
Malignant neoplasm of soft tissue
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Spindle cell rhabdomyosarcoma (RMS) is an aggressive sarcoma type with a predilection for the head and neck and frequent transactivating MYOD1 mutations.
|
31107719 |
2019 |
|
Muscular Dystrophy, Duchenne
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we report a novel MYOD1-converted, urine-derived cells (UDCs) as a novel DMD muscle cell model.
|
30846748 |
2019 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, functions for MyoD1 in GC cell migration and gene expression have not been documented.
|
31831855 |
2019 |
|
Rhabdomyoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Cases were wild type for MYOD1 and no other mutations or rearrangements characteristic of a known subtype of rhabdomyoma or rhabdomyosarcoma were identified.
|
30287926 |
2019 |
|
Premature aging syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>NORAD</i> acts as a negative regulator of PUMILIO (PUM) proteins in the cytoplasm, and we previously showed that loss of <i>NORAD</i> or PUM hyperactivity results in genome instability and premature aging in mice (Kopp et al., 2019).
|
31343408 |
2019 |
|
Hyperactive behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
<i>NORAD</i> acts as a negative regulator of PUMILIO (PUM) proteins in the cytoplasm, and we previously showed that loss of <i>NORAD</i> or PUM hyperactivity results in genome instability and premature aging in mice (Kopp et al., 2019).
|
31343408 |
2019 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, functions for MyoD1 in GC cell migration and gene expression have not been documented.
|
31831855 |
2019 |
|
Critical illness myopathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Upstream regulator analysis revealed that the CIM signature could be a result of the activation of MYOD1, p38 MAPK, or treatment with dexamethasone.
|
30992050 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We show that knockdown of MyoD1 promoted migration and invasion of GC cells, whereas MyoD1 overexpression suppressed migration and invasion.
|
31831855 |
2019 |
|
Secondary Neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
At final follow-up (median = 13.5 months), recurrences (n = 4), metastases (n = 2) or both (n = 1) occurred in seven MYOD1-mutant cases; one had died of disease.
|
30604891 |
2019 |